<DOC>
	<DOCNO>NCT00700336</DOCNO>
	<brief_summary>The phase I part study dose-finding study escalate dos CBP501 combine full-dose cisplatin pemetrexed patient histologically confirm solid malignancy metastatic unresectable standard curative palliative measure exist longer effective would otherwise eligible cisplatin pemetrexed first-line therapy . The maximum tolerated dose ( MTD ) determine base DLTs occur first treatment cycle . Pharmacokinetics triplet combination assess phase I part trial . The phase II part evaluate full-dose cisplatin pemetrexed combine CBP501 ( MTD determine phase I part ) previously untreated , unresectable malignant pleural mesothelioma patient . Patients randomize 2 : 1 ratio pemetrexed , cisplatin CBP501 ( Arm A ) pemetrexed cisplatin ( Arm B ) ; randomization stratify accord histology performance status .</brief_summary>
	<brief_title>Study CBP501 + Pemetrexed + Cisplatin MPM ( Phase I/II )</brief_title>
	<detailed_description />
	<mesh_term>Mesothelioma</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>1 . Signed informed consent obtain prior initiation studyspecific procedures 2 . Phase I : Histologically confirm solid malignancy metastatic unresectable standard curative palliative measure exist longer effective would otherwise eligible cisplatin pemetrexed firstline therapy Phase II : Histologically cytologically confirm diagnosis malignant pleural mesothelioma ( MPM ) , amenable radical resection , receive previous chemotherapy systemic treatment 3 . Measurable disease accord modify Response Evaluation Criteria Solid Tumors ( RECIST , see ) 4 . Male female patient age least 18 year 5 . ECOG Performance Status ( PS ) : 02 6 . Previous anticancer treatment must discontinue least 3 week prior first dose study treatment ( 6 week mitomycin C ; 6 week antiandrogen therapy discontinue prior treatment initiation , exception 8 week bicalutamide ) 7 . Life expectancy great 3 month 8 . Adequate organ function 9 . Female patient childbearing potential must negative pregnancy test use least one form contraception approve Investigator 4 week prior study 4 month last dose study drug . For purpose study , childbearing potential define : `` All female patient unless postmenopausal least one year surgically sterile '' 10 . Male patient must use form barrier contraception approve investigator study 4 month last dose study drug 11 . Ability cooperate treatment followup 1 . Radiation therapy 30 % bone marrow prior entry study 2 . Phase II : Mesothelioma originate outside pleura ( e.g . : peritoneum ) 3 . Absence measurable lesion 4 . The patient ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , symptomatic poorly control cardiac arrhythmia , uncontrolled thrombotic hemorrhagic disorder , serious uncontrolled medical disorder opinion investigator . 5 . Any previous history another malignancy within 5 year study entry ( cure basal cell carcinoma skin cure insitu carcinoma cervix ) 6 . Presence significant central nervous system psychiatric disorder ( ) would hamper patient 's compliance 7 . Evidence peripheral neuropathy &gt; grade 1 accord NCICTCAE Version 3 8 . Treatment investigational agent , participation another clinical trial within 28 day prior study entry 9 . Pregnant breastfeeding patient patient childbearing potential use adequate contraception 10 . Known HIV , HBV , HCV infection 11 . Presence CNS metastasis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2011</verification_date>
	<keyword>malignant pleural mesothelioma</keyword>
	<keyword>solid tumor</keyword>
</DOC>